Primary Osteogenic Sarcoma of the Femur: A Model for the Use of Preoperative Chemotherapy in High Risk Malignant Tumors
- 1 January 1984
- journal article
- research article
- Published by Informa UK Limited in Cancer Investigation
- Vol. 2 (3), 181-192
- https://doi.org/10.3109/07357908409104370
Abstract
The value of adjuvant chemotherapy in primary osteogenic sarcoma (OSA) is still considered controversial by some. One reason may be that various reported series include patients with widely varying prognostic variables. To address this, the effect of chemotherapy on the continuous disease-free (CNED) survival was analyzed in 100 patients aged 21 yr or less with OSA of the femur. This classically poor prognostic group of patients represented 51% of all primary OSA seen at the Memorial Sloan-Kettering Cancer Center during the study interval. This study includes all patients aged 21 yr or less with fully malignant (Grade III---IVI IV) OSA of the femur and no metastases treated from November 1973 through November 1981. The first (T-4) protocol (31 patients) consisted of high dose methotrexate (HDMTX) with leucovorin rescue, cyclophosphamide (Cyc), and adriamycin. In the second (T-7) protocol (23 patients) the dose of HDMTX was increased to 12 glm2 for prepubescent patients, and bleomycin, Cyc, and dactinomycin replaced Cyc. The current (T-10) protocol (46 patients) uses the same CT as T-7, but patients not having a complete response of the primary tumor to preoperative CT. receive additional cisplatinum (120 mg/m2) with adriamycin (30 mg/m2/day for two consecutive days). In 31 patients treated with T-4 the CNED survival was 32% with a minimum follow up of over 7 yr. On T-7, 15/23 patients with femur primaries had a CNED survival of 65% with all of the surviving patients followed for more than 5 yr. The addition of cisplatinum in T-10 has resulted in CNED survival rate of 77% in 34/44 patients (excluding two patients that died CNED during and after treatment); the median follow-up patients who are alive CNED is 33 months, with a minimum of 2 yr follow up on the last patient enteredThis publication has 16 references indexed in Scilit:
- Preoperative chemotherapy for osteogenic sarcoma:Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapyCancer, 1982
- Chemotherapy of Osteosarcoma — An OverviewPublished by Springer Science and Business Media LLC ,1980
- Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcomaCancer, 1977
- PRIMARY OSTEOGENIC-SARCOMA - PATHOLOGIC ASPECTS IN 20 PATIENTS AFTER TREATMENT WITH CHEMOTHERAPY EN BLOC RESECTION, AND PROSTHETIC BONE REPLACEMENT1977
- HIGH-DOSE METHOTREXATE WITH CITROVORUM FACTOR RESCUE - PREDICTIVE VALUE OF SERUM METHOTREXATE CONCENTRATIONS AND CORRECTIVE MEASURES TO AVERT TOXICITY1977
- Adjuvant multiple drug chemotherapy for osteosarcoma of the extremityCancer, 1977
- Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma.Pre-surgical treatment of primary tumor and of overt pulmonary metastasesCancer, 1977
- Study of Adjuvant Chemotherapy in Osteogenic SarcomaThe Journal of Clinical Pharmacology, 1975
- Amputation and Adriamycin in Primary OsteosarcomaNew England Journal of Medicine, 1974
- High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcomaCancer, 1974